Literature DB >> 20305792

Method for Fast CT/SPECT-Based 3D Monte Carlo Absorbed Dose Computations in Internal Emitter Therapy.

S J Wilderman1, Y K Dewaraja.   

Abstract

The DPM (Dose Planning Method) Monte Carlo electron and photon transport program, designed for fast computation of radiation absorbed dose in external beam radiotherapy, has been adapted to the calculation of absorbed dose in patient-specific internal emitter therapy. Because both its photon and electron transport mechanics algorithms have been optimized for fast computation in 3D voxelized geometries (in particular, those derived from CT scans), DPM is perfectly suited for performing patient-specific absorbed dose calculations in internal emitter therapy. In the updated version of DPM developed for the current work, the necessary inputs are a patient CT image, a registered SPECT image, and any number of registered masks defining regions of interest. DPM has been benchmarked for internal emitter therapy applications by comparing computed absorption fractions for a variety of organs using a Zubal phantom with reference results from the Medical Internal Radionuclide Dose (MIRD) Committee standards. In addition, the β decay source algorithm and the photon tracking algorithm of DPM have been further benchmarked by comparison to experimental data. This paper presents a description of the program, the results of the benchmark studies, and some sample computations using patient data from radioimmunotherapy studies using (131)I.

Entities:  

Year:  2007        PMID: 20305792      PMCID: PMC2841294          DOI: 10.1109/TNS.2006.889164

Source DB:  PubMed          Journal:  IEEE Trans Nucl Sci        ISSN: 0018-9499            Impact factor:   1.679


  17 in total

1.  Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy.

Authors:  Marie-Anne Descalle; Christine L Hartmann Siantar; Lucile Dauffy; David W Nigg; Charles A Wemple; Aina Yuan; Gerald L DeNardo
Journal:  Cancer Biother Radiopharm       Date:  2003-02       Impact factor: 3.099

2.  A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I using monte carlo simulation.

Authors:  Michael Ljungberg; Katarina Sjögreen; Xiaowei Liu; Eric Frey; Yuni Dewaraja; Sven-Erik Strand
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

3.  Benchmarking of the dose planning method (DPM) Monte Carlo code using electron beams from a racetrack microtron.

Authors:  Indrin J Chetty; Jean M Moran; Daniel L McShan; Benedick A Fraass; Scott J Wilderman; Alex F Bielajew
Journal:  Med Phys       Date:  2002-06       Impact factor: 4.071

4.  Experimental validation of the DPM Monte Carlo code using minimally scattered electron beams in heterogeneous media.

Authors:  Indrin J Chetty; Jean M Moran; Teamor S Nurushev; Daniel L McShan; Benedick A Fraass; Scott J Wilderman; Alex F Bielajew
Journal:  Phys Med Biol       Date:  2002-06-07       Impact factor: 3.609

5.  Accounting for center-of-mass target motion using convolution methods in Monte Carlo-based dose calculations of the lung.

Authors:  Indrin J Chetty; Mihaela Rosu; Daniel L McShan; Benedick A Fraass; James M Balter; Randall K Ten Haken
Journal:  Med Phys       Date:  2004-04       Impact factor: 4.071

6.  Dose reconstruction in deforming lung anatomy: dose grid size effects and clinical implications.

Authors:  Mihaela Rosu; Indrin J Chetty; James M Balter; Marc L Kessler; Daniel L McShan; Randall K Ten Haken
Journal:  Med Phys       Date:  2005-08       Impact factor: 4.071

7.  Computerized three-dimensional segmented human anatomy.

Authors:  I G Zubal; C R Harrell; E O Smith; Z Rattner; G Gindi; P B Hoffer
Journal:  Med Phys       Date:  1994-02       Impact factor: 4.071

8.  Absorbed fractions in a voxel-based phantom calculated with the MCNP-4B code.

Authors:  H Yoriyaz; A dos Santos; M G Stabin; R Cabezas
Journal:  Med Phys       Date:  2000-07       Impact factor: 4.071

9.  Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Michael Ljungberg; Kenneth F Koral; Kenneth Zasadny; Mark S Kaminiski
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

10.  Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Authors:  Robert M Sharkey; Arnold Brenner; Jack Burton; George Hajjar; Stephen P Toder; Abass Alavi; Alexander Matthies; Donald E Tsai; Stephen J Schuster; Edward A Stadtmauer; Myron S Czuczman; Dominick Lamonica; Françoise Kraeber-Bodere; Beatrice Mahe; Jean-François Chatal; André Rogatko; George Mardirrosian; David M Goldenberg
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

View more
  18 in total

1.  Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.

Authors:  David M Howard; Kimberlee J Kearfott; Scott J Wilderman; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2011-09-22       Impact factor: 3.099

2.  Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.

Authors:  Hanan Amro; Scott J Wilderman; Yuni K Dewaraja; Peter L Roberson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

3.  Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Authors:  Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

4.  Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Authors:  Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2017-10-30       Impact factor: 3.099

5.  Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images.

Authors:  F Botta; A Mairani; R F Hobbs; A Vergara Gil; M Pacilio; K Parodi; M Cremonesi; M A Coca Pérez; A Di Dia; M Ferrari; F Guerriero; G Battistoni; G Pedroli; G Paganelli; L A Torres Aroche; G Sgouros
Journal:  Phys Med Biol       Date:  2013-11-21       Impact factor: 3.609

6.  Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

7.  Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.

Authors:  Yuni K Dewaraja; Theresa Devasia; Ravi K Kaza; Justin K Mikell; Dawn Owen; Peter L Roberson; Matthew J Schipper
Journal:  J Nucl Med       Date:  2019-05-30       Impact factor: 10.057

8.  Impact of 90Y PET gradient-based tumor segmentation on voxel-level dosimetry in liver radioembolization.

Authors:  Justin K Mikell; Ravi K Kaza; Peter L Roberson; Kelly C Younge; Ravi N Srinivasa; Bill S Majdalany; Kyle C Cuneo; Dawn Owen; Theresa Devasia; Matthew J Schipper; Yuni K Dewaraja
Journal:  EJNMMI Phys       Date:  2018-11-30

9.  Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

10.  Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine.

Authors:  James C Sisson; Yuni K Dewaraja; Eric J Wizauer; Thomas J Giordano; Anca M Avram
Journal:  Thyroid       Date:  2009-03       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.